☆ 4.7 Article

Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve

JOURNAL OF MEDICINAL CHEMISTRY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Chemistry, Medicinal

Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers

Zehui Zhou et al.

Summary: The linker moiety of a PROTAC molecule is crucial for its degradation activity, target selectivity, and physico-chemical properties. Understanding the underlying mechanisms of linker modification is important for enhancing PROTAC degradation and developing novel chemotherapies.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

添加到收藏夹

Article Chemistry, Medicinal

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

Zhen Wang et al.

Summary: Protein kinases have been proven to be effective targets for cancer drug discovery, but most drugs inhibit kinase catalytic activity by binding to ATP-site. Recent studies have shown that kinases also have noncatalytic functions, which play important roles in cellular signaling and cell fate controls. Small-molecule modulators targeting the noncatalytic functions of kinases have emerged as promising therapeutic strategies. This article summarizes the noncatalytic functions of kinases and discusses the progress in developing small-molecule modulators. It is speculated that targeting the noncatalytic functions could open a new direction for kinase-based drug discovery.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Cell Biology

Roles of PIKfyve in multiple cellular pathways

Pilar Rivero-Rios et al.

Summary: Phosphoinositide signaling lipids are essential for eukaryotes, and their low abundance has made their study challenging. This article focuses on two of the least abundant phosphoinositides, PI(3,5)P-2 and PI(5)P, which play critical roles in cellular homeostasis, membrane trafficking, and transcription. The levels of these lipids are tightly regulated by a protein complex consisting of PIKfyve, Fig4, and Vac14. Mutations in this complex that reduce PI(3,5)P2 and PI(5)P have been linked to human diseases, particularly those affecting the nervous system. Despite this, PIKfyve inhibitors that decrease these phosphoinositides are currently being tested as potential treatments for neurodegenerative diseases, as well as other diverse conditions including certain cancers and SARS-CoV2 infection. A more comprehensive understanding of the pathways regulated by PIKfyve will be crucial for understanding the roles of PI(3,5)P-2 and PI(5)P in normal human physiology and disease.

CURRENT OPINION IN CELL BIOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

Lanbo Xiao et al.

Summary: The SWI/SNF complex plays a crucial role in chromatin remodeling and is altered in over 20% of cancers. A newly developed proteolysis-targeting chimera (PROTAC) named AU-15330 can degrade the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4, leading to inhibition of tumor growth in prostate cancer cells that are sensitive to this degradation. Impeding SWI/SNF-mediated enhancer accessibility could be a promising therapeutic approach for enhancer-addicted cancers.

NATURE (2022)

添加到收藏夹

Article Cell Biology

The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19

Maksim V. Baranov et al.

Summary: Apilimod, a PIKfyve inhibitor, is undergoing clinical trials for COVID-19 treatment. Despite its potential to prevent viral invasion, it also blocks antiviral immune responses. This may exacerbate the immunosuppression seen in many COVID-19 patients.

CELLS (2021)

添加到收藏夹

Article Oncology

Combined Inhibition of p38MAPK and PIKfyve Synergistically Disrupts Autophagy to Selectively Target Cancer Cells

Constandina E. O'Connell et al.

Summary: The study revealed that PIKfyve and p38MAPK cooperate to regulate lysosome homeostasis, and their combined inhibition synergistically blocks autophagy to reduce cancer cell viability in vitro and in vivo.

CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer

Yuanyuan Qiao et al.

Summary: ESK981 is an effective MTKI that enhances therapeutic response in prostate cancer by inhibiting autophagy. It upregulates CXCL10 expression to promote T cell infiltration, enhancing the efficacy of immune checkpoint blockade therapy.

NATURE CANCER (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery

George M. Burslem et al.

CELL (2020)

添加到收藏夹

Article Cell Biology

The PIKfyve complex regulates the early melanosome homeostasis required for physiological amyloid formation

Christin Bissig et al.

JOURNAL OF CELL SCIENCE (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations

Ognian C. Ikonomov et al.

TOXICOLOGY AND APPLIED PHARMACOLOGY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyI)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyppyrrolidine-2-carboxamide (VH298)

Pedro Soares et al.

JOURNAL OF MEDICINAL CHEMISTRY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation

Diego Sbrissa et al.

PLOS ONE (2018)

添加到收藏夹

Article Cell Biology

PIKfyve activity regulates reformation of terminal storage lysosomes from endolysosomes

Christin Bissig et al.

TRAFFIC (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Philipp M. Cromm et al.

CELL CHEMICAL BIOLOGY (2017)

添加到收藏夹

Article Hematology

Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma

Sophia Gayle et al.

BLOOD (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

PIKfyve inhibition increases exosome release and induces secretory autophagy

Nina Pettersen Hessvik et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1

Angela Oppelt et al.

BIOCHEMICAL JOURNAL (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

The PIKfyve-ArPIKfyve-Sac3 triad in human breast cancer: Functional link between elevated Sac3 phosphatase and enhanced proliferation of triple negative cell lines

Ognian C. Ikonomov et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor Signaling

Xinming Cai et al.

CHEMISTRY & BIOLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Inhibition of PIKfyve by YM-201636 Dysregulates Autophagy and Leads to Apoptosis-Independent Neuronal Cell Death

Sally Martin et al.

PLOS ONE (2013)

添加到收藏夹

Article Rheumatology

A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis

Sarah Krausz et al.

ARTHRITIS AND RHEUMATISM (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

YM201636, an inhibitor of retroviral budding and PIKfyve-catalyzed PtdIns(3,5)P2 synthesis, halts glucose entry by insulin in adipocytes

Ognian C. Ikonomov et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)

添加到收藏夹

Article Cell Biology

PIKfyve Regulation of Endosome-Linked Pathways

Jane de Lartigue et al.

TRAFFIC (2009)

添加到收藏夹

Review Cell Biology

PIKfyve: Partners, significance, debates and paradoxes

Assia Shisheva

CELL BIOLOGY INTERNATIONAL (2008)

添加到收藏夹

Article Biochemistry & Molecular Biology

A selective PIKfyve inhibitor blocks PtdIns(3,5) P2 production and disrupts endomembrane transport and retroviral budding

Harold B. J. Jefferies et al.

EMBO REPORTS (2008)

添加到收藏夹

Article Hematology

Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor

Yumiko Wada et al.

BLOOD (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.